



Correction

Article title: *Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress*

Authors: Girija Dasmahapatra, Dmitry Lembersky, Mohamed Rahmani, Lora Kramer, Jonathan Friedberg, Richard I. Fisher, Paul Dent & Steven Grant

Journal: *Cancer Biology & Therapy*

DOI: <https://doi.org/10.4161/cbt.8.9.8131>

In the version of *Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress* by Girija Dasmahapatra, Dmitry Lembersky, Mohamed Rahmani, Lora Kramer, Jonathan Friedberg, Richard I. Fisher, Paul Dent & Steven Grant published online May 11, 2009 and in print in its official publication Issue 8, Volume 9, a research misconduct finding against the first author affected Figure 4B of this manuscript. Specifically, blots in Figure 4B were inappropriately labeled and duplicated. The remaining authors have now repeated the experiments and provided corrected figures.

The published online version has been corrected to show the correct figure, which show treatment of SUDHL16 cells with bortezomib and HA14-1 led to an increase in expression of phospho-JNK and phospho-c-Jun, and co-administration of the JNK inhibitor IB1 attenuated both of these responses (left panel). IB1 also diminished expression of bortezomib/HA-mediated PARP cleavage (right panel). These results are consistent with the original findings reported in the manuscript.

The authors apologize for any inconvenience caused by this error.